Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Learn more about whether Alvotech or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which ...

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Its product portfolio comprises Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. Thus, its product ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over the trial’s batoclimab. Wednesday, Immunovant, Inc. (NASDAQ ...

and ImmunoVent (batoclimab) are in late-stage development. AZ/Alexion meanwhile is working on a subcutaneous formulation of Soliris follow-up Ultomiris (ravulizumab) for gMG, and UCB is working on ...

Among domestic companies, HANALL BIOPHARMA is developing ‘batoclimab’ as a treatment for various autoimmune diseases in partnership with U.S. partner Immunovant. The company announced this ...

Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat ...